As UCB grows, CEO Tellier pledges to keep chasing innovation

26 July 2018

UCB (Euronext: UCB) rose 1.2% on Thursday after it published financial results for the first half of 2018. The Belgian drugmaker, which specializes in immunology and neurology, reported 5% sales increases and a 2% rise in overall revenue over the first half of 2017.

The two stars of UCB's catalog — rheumatic therapy Cimzia (certolizumab pegol) and anticonvulsant Vimpat (lacosamide) — both outperformed their 2017 figures, the former by 2% and the latter by 10%. Unusually, these gains weren't driven by American sales. Cimzia drew in less revenue from the USA than in the first half of last year, while Vimpat secured 21% growth in Europe, 34% growth in other international markets and just 5% from the USA.

In conversation with The Pharma Letter, Jean-Cristophe Tellier — UCB's chief executive since 2015 — drew attention to the success of the company's core therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK